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Interactions of human mesangial cells with IgA and IgA-con- vated levels of IgA1 and IgA1-containing circulating im-
taining circulating immune complexes. mune complexes (CIC) are found in sera of most IgAN
Background. IgA nephropathy (IgAN) is characterized by patients [4–7]. IgA1-containing immune deposits are ob-IgA1-containing immune complexes in mesangial deposits and
served in the renal mesangium (usually with C3 comple-in the circulation. The circulating immune complexes (CIC) are
ment component, and often with IgG, IgM, or both) [8].composed of galactose- (Gal) deficient IgA1 and IgG or IgA1
antibodies specific for the Gal-deficient IgA1; interactions of The progression of the disease is characterized by prolif-
these CIC with mesangial cells (MC) were studied. eration of mesangial cells and expansion of extracellular
Methods. Binding, internalization, and catabolic degrada- matrix (ECM), leading ultimately to glomerular sclerosistion of myeloma IgA1 protein as a standard control and the
[9]. About 30 to 40% of IgAN patients develop kidneyisolated CIC were studied using human MC, hepatoma cell line
failure within 20 years of clinical onset; these patients re-HepG2 expressing the asialoglycoprotein receptor (ASGP-R),
and monocyte-like cell line U937 expressing the Fc-R (CD89). quire either dialysis or kidney transplantation [10]. IgAN
Biochemical and molecular approaches were used to assess recurs in approximately 50 to 60% of patients after kid-
expression of CD89 and ASGP-R by MC.
ney transplantation [11]. On the other hand, a kidneyResults. At 4C, radiolabeled IgA1 bound to MC and HepG2
transplanted from a donor with subclinical IgAN to acells in a dose-dependent and saturable manner. The binding
was inhibited by IgA-containing CIC or excess IgA1 or its Fc patient without IgAN clears the immune deposits after
fragment but not by the Fab fragment of IgA1. At 37C, the several weeks [12]. It is therefore apparent that IgAN
cell-bound IgA1 was internalized and catabolized. In addition arises from formation and deposition of immune com-
to IgA1, HepG2 cells also bound (in a Ca2-dependent man-
plexes rather than from a defect inherent in the kidneyner), internalized, and catabolized asialoorosomucoid (ASOR),
[2, 4–6, 8, 13–16].other asialo-(AS)-glycoproteins, and secretory component (SC).
The binding by MC appeared to be restricted to IgA1 or AS- IgA immune deposits are likely derived from CIC,
IgA1 and was not Ca2-dependent. Furthermore, MC and HepG2 however, the nature of the antigens in the CIC is un-
cells internalized and catabolized IgA1-containing CIC. Using known [4, 5, 14]. Based on our experimental data, weRT-PCR with ASGP-R- or CD89-specific primers, mRNAs of
postulated that aberrant glycosylation of IgA1 immuno-the two respective genes were not detected in MC.
globulins in the circulation of IgAN patients leads toConclusions. The data showed that the ability of MC to bind
IgA1 and IgA1-containing CIC in vitro was mediated by an formation of CIC [6]. Incomplete galactosylation of
IgA receptor that was different from CD89 or ASGP-R and O-linked glycans in the IgA1 hinge region results in the
had a higher affinity for IgA-CIC than for uncomplexed IgA. exposure of underlying neo-antigenic N-acetylgalactos-
amine (GalNAc) [6, 16] that is recognized by naturally
occurring antibodies (IgG or IgA1 specific for GalNAc)
Idiopathic IgA nephropathy (IgAN) is the most com-
[6]. We further postulated that these CIC deposit onmon primary glomerulonephritis in the world [1–3]. Ele-
mesangial cells (MC), resulting in MC proliferation and
overexpression of extracellular matrix [15, 17]. Recently,
1 See Editorial by Go´mez-Guerrero, Suzuki, and Egido, p. 715. highly undergalactosylated IgA1 was detected in the
mesangial deposits in IgAN patients, and this furtherKey words: renal mesangial cells, circulating immune complexes, IgA
nephropathy, glomerulonephritis. supports our hypothesis [18, 19].
In this regard, understanding the mechanisms by whichReceived for publication March 26, 2001
CIC bind to MC is of utmost importance [10]. Severaland in revised form March 7, 2002
Accepted for publication March 22, 2002 studies evaluating the nature of an IgA receptor ex-
pressed on MC have provided conflicting results. Some 2002 by the International Society of Nephrology
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found FcR (CD89) or the asialoglycoprotein receptor (a) positive staining for vimentin, and (b) negative stain-
(ASGP-R) expressed by cultured MC or in some renal ing for factor VIII-related antigen and cytokeratin (to ex-
biopsy samples from IgAN patients [20–23]. Other stud- clude contamination with endothelial and epithelial cells,
ies showed binding of IgA1 to MC but did not confirm respectively). Human hepatocarcinoma cell line HepG2
expression of CD89 by MC [24–27]. Most of these studies and human monocytic cell line U937 (both obtained from
were conducted using uncomplexed [monomeric (m), ATCC, Rockville, MD, USA) were maintained in RPMI
polymeric (p)] or heat-aggregated IgA1. However, in light 1640, 10% FCS, and antibiotics [28]. MC for binding ex-
of recent findings on the role of CIC containing aberrantly periments were serum starved (medium contained only
glycosylated IgA1 in the pathogenesis of IgAN [6, 10, 0.5% FCS) 24 hours before the experiment.
17–19], it is important to examine interactions of MC
Isolation of IgA1 proteins, their Fab andwith not only free IgA1 and de-galactosylated IgA1, but
Fc fragments, and IgA1-containing CICalso with galactose-deficient IgA1 bound in CIC.
Our study reports that human MC in primary culture IgA1 and IgA2 myeloma proteins were isolated from
bind, internalize, and catabolically degrade IgA1 and plasma of several different patients with multiple mye-
IgA1-containing CIC. HepG2 cells expressing ASGP-R loma by precipitation with ammonium sulfate, starch-
[28, 29] and U937 expressing FcR (CD89) served as a block electrophoresis, and size-exclusion and ion-exchange
positive controls. ASGP-R is a hetero-oligomer of two chromatography [6, 33]. The polymeric forms of IgA1
subunits, H1 and H2, encoded by separate genes [30, 31]. (Mce) and IgA2 (Fel) were used [6] and their polymeric
ASGP-R on hepatocytes binds glycoproteins with termi- character was demonstrated by size-exclusion chroma-
nal Gal or GalNAc residues, and the bound glycopro- tography and sodium dodecyl sulfate (SDS)-gel electro-
teins are subsequently internalized and catabolized [28, phoresis under non-reducing conditions. The Fab frag-
29, 32]. A standard probe to detect ASGP-R is asialo- ment of IgA1 myeloma protein (Ste) was prepared by
orosomucoid (ASOR) [28, 29] that is rapidly internalized cleavage with IgA1 protease from Haemophilus influen-
and catabolized by hepatocytes upon binding [6, 29]. zae (HK50); Fab and Fc fragments of IgA1 (Mce) were
ASGP-R also binds secretory component (SC) [28], a generated using IgA1 protease from Neisseria gonor-
highly glycosylated fragment of the pIg receptor (pIgR) rhoeae [39, 40]. The resulting Fab and Fc fragments were
that remains bound to secretory IgA or IgM [33–35]. purified by size-exclusion chromatography [33] and their
Eventual catabolic degradation of SC or ASOR by MC purity was verified by SDS electrophoresis.
thus would confirm the previously postulated presence Fractions rich in Gal-deficient IgA1-containing CIC
of ASGP-R on MC [21]. FcR (CD89) is a glycoprotein
were prepared from sera of IgAN patients by size-exclu-
expressed on myeloid cells that binds both IgA sub-
sion chromatography on a calibrated Superose 6 columnclasses [36]. Binding of IgA to the FcR also may lead
[6]; high-molecular-mass fractions reactive with Helixto internalization and catabolic degradation [28]. Using
aspersa (HAA) lectin (which binds terminal GalNAc ofthese control cells, we have demonstrated differences in
Gal-deficient O-glycans of IgA1; Sigma, Chemical Com-properties and binding specificities of IgA1 receptors
pany, St. Louis, MO, USA) and containing IgA and IgGexpressed by human MC, HepG2 and U937 cells. Our
were pooled [6].observations indicated that the ability of MC to bind
Asialo- (AS) IgA1, asialo-agalacto IgA1 and ASORIgA1 and IgA1-containing CIC in vitro is mediated by
were prepared from native proteins by incubation witha new type of IgA receptor with higher affinity for IgA-
neuraminidase (from Vibrio cholerae) and -galactosi-CIC than for uncomplexed IgA.
dase (from bovine testes that preferentially cleaves 1,3
linkages) [6, 16, 28, 41]. SC was isolated from human
METHODS milk [33]. IgG was purified from normal human serum
by ammonium sulfate precipitation, and subsequent ion-Cells
exchange (DEAE-cellulose) and affinity chromatogra-Human MC were isolated from the normal portions
phy on a Protein-G column [42].of kidney cortexes of tumor nephrectomy specimens (2
To prepare in vitro a complex of IgG bound to Gal-cell cultures) as described before [37, 38] or purchased as
deficient pIgA1, we incubated 125I-labeled degalactosy-primary cells (2 cell cultures) from a commercial source
lated IgA1 (Mce) [6] with purified human IgG with anti-(Clonetics, San Diego, CA, USA). Cells from passages
GalNAc activity [6]. Free IgA1 was separated from the3 to 5 were used in our experiments. MC were maintained
IgG-IgA1 complexes by size-exclusion chromatographyin RPMI 1640 supplemented with 20% fetal calf serum
on a Superose 6 column. The fractions containing IgG(FCS), l-glutamine (2 mmol/L), penicillin G (100 U/mL),
bound to the radiolabeled IgA1 were identified by usingstreptomycin (0.1 mg/mL) in humidified 5% CO2 atmo-
Protein-G-coated Immulon Removawell strips (Dyna-sphere at 37C. Purity and identification of MC was based
on cell morphology and immunohistochemical features: tech Laboratories, Alexandria, VA, USA) and a Packard
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model 5110 gamma spectrometer (Packard Instrument HEPES buffer, lysed with a polyacrylamide gel electro-
phoresis loading buffer containing 2% SDS, and ana-Company, Downers Grove, IL, USA).
lyzed by SDS-polyacrylamide gel electrophoresis (SDS-
Radioiodination and tetramethylrhodamine PAGE), using 1.5 mm thick vertical slab gels (20 
isothiocyanate (TRITC)-labeling 20 cm) with 5 to 20% polyacrylamide gradient [28]. The
gels were fixed, frozen with dry ice, and sliced with a gelProteins were radiolabeled with carrier-free Na125I by
slicer. The radioactivity in 1-mm sections was measuredthe lactoperoxidase method [43]. The excess free Na125I
by a gamma spectrometer.was separated from the protein by size-exclusion chro-
matography on a column of Sephadex G-25 [28]. Confocal microscopy
IgA1 (Mce) was TRITC-labeled using 0.02 mg TRITC
Mesangial cells grown on a microscope slide were incu-per mg protein in 2% bicarbonate buffer, pH 8.2. After
bated with TRITC-labeled IgA1 (Mce; 10 g) overnightovernight incubation, free TRITC was removed on a
at 4C, extensively washed with RPMI medium containingcolumn of Sephadex G-50 and the TRITC-IgA1 conju-
0.5% FCS and then incubated at 37C for four hours,gate was isolated using ion-exchange chromatography
followed by incubation at room temperature for twoon a column of DEAE-cellulose. The TRITC-labeled
hours. Imaging was performed on a Leica DMIRBE in-
protein was aliquoted and stored at 70C. verted epifluorescence/Nomarski microscope outfitted with
Leica TCS NT Confocal optics. The system is equippedBinding experiments
with UV, argon ion, krypton ion, and helium/neon lasers
Mesangial cells (or HepG2 cells) grown in 24-well plates for imaging in a wide range of blue, red, and far-red
(60-80% confluent) were washed twice with 20 mmol/L fluorescence. The laser was set to optimal TRITC exci-
HEPES buffer, pH 7.3, containing 140 mmol/L NaCl, tation wavelength to observe the internalized TRITC-
0.8 mmol/L MgCl2, 0.34 mmol/L K2HPO4, 0.34 mmol/L IgA1.
KH2PO4, (buffer A), and incubated with a radiolabeled
Reverse transcription-polymerase chainprotein in 0.2 mL buffer B [buffer A supplemented with
reaction (RT-PCR)2.7 mmol/L CaCl2 and 1% bovine serum albumin (BSA)]
on ice for one hour [28]. Buffer B without CaCl2 supple- Total RNA isolated from the cells (MC, HepG2, and
ment also was used in some experiments, as described U937) with RNA-Stat-60 reagent (Tel-Test, Friends-
in the text. In the inhibition experiments, MC were pre- wood, TX, USA) was used for RT-PCR. HepG2 and
U937 cells served as controls for ASGP-R and CD89incubated for one hour with inhibitors on ice, before
expression, respectively. First-strand cDNA synthesisradiolabeled IgA1 was added and incubated for another
was performed at 42C for 15 minutes, followed by 37Cone hour. Following extensive washing with buffer B,
for 45 minutes using murine leukemia virus reverse tran-cells were lysed with 0.4 mL 0.3 N NaOH and the radioac-
scriptase and oligo(dT)16 as the primer. The cDNA wastivity of the lysate was determined in a  spectrometer.
amplified using the following primers that we designatedCell count was determined with cells released by trypsin/
based on the sequences of the correspond ing genesethylenediaminetetraacetic acid (EDTA) treatment us-
submitted to GeneBank [30, 31, 44] for Fc receptoring a hemocytometer.
(CD89): CD89F 5	-AGCACGATGGACCCCAAACA
GA-3	; CD89R 5	-CTGCCTTCACCTCCAGGTGTT-3	,Catabolic degradation of internalized proteins
and the following primers for H1 and H2 genes encod-Mesangial cells and HepG2 in tissue culture flasks were
ing the two ASGP-R subunits: H1F 5	-CTGGACAATincubated with radiolabeled proteins (1 g of ASOR,
GAGGAGAGTGAC-3	; H1R 5	-TTGAAGCCCGTCAS-IgA1, or immune complexes) in 1 mL buffer B at
TCGTAGTC-3	; H2F CCTGCTGCTGGTGGTCATC37C for four hours. Radioactivity was determined in (a)
TG-3	; H2R 5	-CCCATTTCCAAGAGCCATCAC-3	.incubation medium, (b) cells washed and released by A pair of primers specific to -actin (F 5	-TTCCAGCC
trypsinization, and (c) released cells after additional tryp- TTCCTTCCTGG-3	; R 5	-TTGCGCTCAGGAGGAG
sinization to remove protein bound on cell surface. Cata- CAA-3	) was used as a control. PCR was performed in a
bolic degradation was expressed as percentage of total DNA thermal cycler using 94C melting, 60C annealing,
radioactivity not precipitable by 10% trichloroacetic acid and 72C extension temperatures for 35 cycles. PCR
(TCA; from incubation medium or cell lysate, as speci- amplicons were analyzed on 2% NuSieve 3:1 agarose
fied in the text) [28]. Protein in the cell lysate was deter- gels.
mined spectrophotometrically using a BioRad assay (Bi-
oRad, Hercules, CA, USA) with BSA as the standard.
RESULTSTo determine molecular masses of proteins cataboli-
Binding of IgA1 and IgA1-containing CIC to MCcally degraded, MC were incubated in 2 mL HEPES
buffer, pH 7.3 containing 1% BSA with 10 g 125I-labeled To determine binding characteristics of IgA1, MC were
incubated for one hour on ice with various concentra-IgA1 at 37C for 16 hours. The cells were washed with
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Fig. 1. Binding of 125I-labeled IgA1 (Mce) myeloma protein () and
125I-labeled IgA1 (Mce) with partially degalactosylated and desialylated
O-linked glycans ( ) to mesangial cells (MC). MC were incubated for
one hour on ice with 1 g radiolabeled proteins. Cells were washed and
Fig. 2. Isolation of Gal-deficient IgA1 containing CIC from serum ofthe bound radioactivity determined as described in the Methods section.
an IgAN patient. Serum (0.5 mL) was fractionated on a Superose 6
column (0.9  60 cm), 0.25 mL fractions were collected and analyzed
by ELISA for IgA (), IgG (), and reactivity with HAA lectin (;
tions of radiolabeled pIgA1 (Mce) myeloma protein. specific for terminal GalNAc, thus reacting with Gal-deficient IgA1).
Fractions containing CIC with aberrantly glycosylated IgA1 (molecularConsistent with earlier reports, the binding of the pIgA1
mass about 700 to 900 kD) were pooled and used in the experiments.to MC was dose-dependent and saturable. The binding
of radiolabeled pIgA1 was inhibited by 68% using a 150-
fold excess of unlabeled pIgA1. Analyses of IgA1 bind-
ing to MC using a Scatchard plot (not shown) suggested not by the Fab fragment of IgA1 (that contained a por-
a single population of receptors with approximately 5  tion of the hinge region). Surprisingly, CIC containing
105 binding sites per cell and Ka 4.79  106 mol/L1. The aberrantly glycosylated IgA1 appeared to be better in-
calculations were based on the assumption that pIgA1 hibitors than uncomplexed monomeric or polymeric IgA1
(Mce) was predominantly polymeric, as judged from its (Fig. 3A). The same amount of uncomplexed IgA1 (Gal-
elution profile on a calibrated size-exclusion high pres- deficient or normally glycosylated) had no significant
sure liquid chromatography (HPLC) column (TSK 5000). inhibitory effect (data not shown), suggesting that prop-
Furthermore, we assumed that each receptor bound only erties such as spatial organization of IgA1 in CIC may
one IgA1 molecule. play a role in MC binding. By comparing the inhibitory
Because the mesangial immune deposits in IgAN activity of Fab and Fc portions of IgA1, respectively, we
patients contain aberrantly glycosylated (Gal-deficient concluded that IgA1 bound to a MC IgA receptor by its
O-linked glycans) IgA1 [18, 19], we examined MC bind- Fc portion (Fig. 3B). This is consistent with our finding
ing of Gal-deficient IgA1 myeloma protein. The binding that both IgA subclasses (IgA1 and IgA2) bound to MC
of IgA1 that was modified by treatment with neuramini- (data not shown).
dase and -galactosidase (that removes preferentially The results in the prior section suggested better bind-
1,3 bound Gal) was more than twofold greater com- ing of IgA1 in CIC compared with free IgA1. To verify
pared with the unmodified control (Fig. 1). In sera of this finding, sera from three IgAN patients were fraction-
IgAN patients, however, the aberrantly glycosylated ated using size-exclusion chromatography on a calibrated
IgA1 [16, 45–48] is not free, but rather is complexed Superose 6 column and analyzed for IgA, and for reac-
with IgG (or IgA1) in CIC [5, 6, 16]. To prepare IgA1- tivity with HAA. The fractions corresponding to mIgA
containing CIC, serum from an IgAN patient was frac- and to IgA complexed in CIC were incubated with MC
tionated using size-exclusion chromatography. Fractions grown on microscope slides. After three hours of incuba-
with Gal-deficient IgA1 were identified with GalNAc- tion at 4C, MC were washed with phosphate-buffered
specific lectin (HAA) in ELISA (Fig. 2). The HAA- saline (PBS) and stained with TRITC-conjugated F(ab	)2
reactive fractions (CIC of molecular mass 700 to 900 kD), fragment of anti-human IgA antibody and examined
designated as CIC containing Gal-deficient IgA1, were with a fluorescence microscope. MC incubated with CIC
pooled and used in further experiments. showed strong IgA binding, while MC incubated with
Binding of radiolabeled Gal-deficient pIgA1 was in- uncomplexed IgA exhibited only background-level fluo-
rescence.hibited by unlabeled Gal-deficient pIgA1 (Fig. 3A), but
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Fig. 3. Inhibition of 125I-labeled Gal-deficient pIgA1 (Mce) binding to MC. MC grown to 80% confluence in a 24-well plate were pre-incubated
with inhibitors for one hour on ice and then about 1 g radiolabeled protein was added. Cells were washed and the bound radioactivity was
determined as described in Methods. (A) Control is no inhibitor, and inhibitors are Gal-deficient pIgA1 Mce (100 g), mIgA from serum of an
IgAN patient (50 g), and Gal-deficient-IgA1-containing CIC from serum of an IgAN patient (1 g). (B) Control is no inhibitor, and inhibitors
include Gal-deficient pIgA1 Mce (100 g), Fab fragment of IgA1 (100 g), and Fc fragment of IgA1 Mce (100 g).
These results indicated that IgA1 bound to MC through
the Fc part of its molecule because IgA1 or its Fc frag-
ment, but not its Fab fragment, inhibited IgA binding.
Furthermore, abnormalities of O-linked glycans of IgA1
and spatial organization of IgA1 molecules clustered in
CIC influenced binding to MC, favoring IgA in CIC over
uncomplexed IgA.
Catabolism and internalization of IgA1 by MC
To detect potential degradation products of cell-asso-
ciated and internalized IgA1, the radiolabeled protein
was added to MC and incubated for 16 hours; the cells
were then washed, lysed, and the lysate was analyzed by
SDS gel electrophoresis under non-reducing conditions
(Fig. 4). Generation of protein fragments smaller than
30 kD was observed after incubation with MC, indicating
catabolic degradation of the 125I-labeled IgA1. This find-
ing is consistent with decreased TCA-precipitable radio-
activity. Fig. 4. Catabolism of 125I-labeled IgA1 (Mce) by MC. About 10 g
125I-labeled protein was added to the cells in tissue culture flask andTo visualize internalization of IgA1 by MC, we incu-
incubated in 2 mL HEPES buffer with 1% BSA at 37C for 16 hours.bated MC grown on a microscope slide with TRITC- The cells were then washed, and lysed using 2% SDS buffer and the
labeled IgA1. The cells were then fixed and observed with lysate was analyzed by SDS gel electrophoresis under non-reducing
conditions (solid line). The distribution of radioactivity in the gel wasa confocal laser scanning microscope. Many MC showed
determined by assaying the radioactivity of 1-mm sections of the gel inintracellular fluorescent vesicles, which indicated inter- a gamma counter. Control 125I-labeled IgA1 (dotted line) was electro-
nalization of IgA1 (Fig. 5). phoresed in parallel. Migration of standards is shown by arrows.
Internalization and catabolism of AS-IgA1, ASOR,
and SC by HepG2 and MC ASGP-R [28, 29] and served as a positive control. The
cell cultures were then washed, treated with trypsin toAsialoglycoprotein receptor has been reported as one
release cells from the flasks and surface-bound radiola-of the receptors responsible for binding of IgA1 to MC
beled protein from cells. After further washing, the cells[21]. To verify this report, we incubated 125I-labeled AS-
IgA1 with MC and HepG2 cells. HepG2 cells express were lysed with NaOH. The internalized protein was de-
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Fig. 5. Confocal laser scanning photomicro-
graph of IgA1 internalized by a MC. MC grown
on a microscope slide were incubated with
TRITC-labeled IgA1 (Mce; 10 g) overnight
at 4C, extensively washed with RPMI 1640
medium containing 0.5% FCS and incubated
at 37C for four hours, followed by incubation
at room temperature for two hours. A single
MC is shown with fluorescent vesicles in the
cytoplasm. Bar depicts 20 m.
tected as radioactivity in the trypsin-treated and washed MC was internalized 144-fold more effectively by HepG2
than MC (Fig. 6). Likewise, the catabolic degradationcells. AS-IgA1 was internalized by both cell cultures
was more effective in HepG2 cells. Furthermore, it was(Fig. 6). Under the same conditions, HepG2 internalized
also reported that HepG2 internalize and catabolize SCsixfold more AS-IgA1 per mg cell protein than did MC.
[28]. Therefore, we compared catabolism of SC and IgA1To estimate the kinetics of catabolic degradation of inter-
in MC (Table 1). More than 99% of original 125I-labelednalized proteins, percentage of the radiolabeled protein
SC incubated with MC remained intact, while the origi-not precipitable with TCA was determined. HepG2 cells
nal 125I-labeled IgA1 was partially (about 13%) cataboli-catabolized 47% of the internalized AS-IgA1 compared
cally degraded during the four-hour incubation. Theseto 39% for MC. Unlike with HepG2, the binding and
data demonstrated that SC, but not IgA1, escaped cata-
internalization of AS-IgA1 by MC was not Ca2-depen- bolic degradation by MC. Therefore, ASGP-R is missing
dent (data not shown). or nonfunctional on MC.
Earlier studies demonstrated that ASGP-R on hepato-
Binding and internalization of IgA1-containingcytes or HepG2 cells is responsible for rapid internaliza-
CIC by HepG2 and MCtion and catabolic degradation of ASOR [28]. We investi-
gated whether ASOR also is internalized and catabolized Studies described above indicated that IgA1-contain-
ing CIC bound to MC more effectively than free IgA1.by MC. 125I-labeled ASOR incubated with HepG2 and
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Fig. 6. Internalization of 125I-labeled ASOR and 125I-labeled asialo-
(AS) IgA1 (Mce) by HepG2 and MC. About 1 g of each radiolabeled Fig. 7. HepG2 and MC cell-associated (bound and internalized)
protein was added to the cells in tissue culture flask and incubated in 1 125I-labeled Gal-deficient IgA1-containing CIC isolated from serum of
mL buffer B at 37C for four hours. Cells were washed and radioactivity an IgAN patient () and CIC from a healthy control ( ). About 1 g
measured after trypsinization to release surface-bound molecules. Re- aliquots of the radiolabeled proteins were added to the cells in tissue
sults represent an average from experiments conducted in triplicates. culture flasks and incubated in 1 mL buffer B at 37C for four hours.
Cells were washed before the cell-associated radioactivity was mea-
sured. Results are averages from experiments conducted in triplicates.
Table 1. Catabolism of radioiodinated secretory component (SC)
and IgA1 (Mce) by human mesangial cells
TCA precipitable protein %
SC IgA1 (Mce)
Before incubation 93.9 95.6
After incubation 93.0 82.8
One-microgram aliquots of the SC or IgA1 proteins were added to MC in
cultivation flasks and incubated for 4 hours at 37C. Then, the supernatant was
collected, precipitated with TCA, and the intact protein (TCA-precipitable radio-
activity measured using gamma counter) was expressed as % of TCA-precipitable
radioactivity. The experiment was conducted in triplicate.
To examine the possible role of liver cells and ASGP-R
in binding and processing of these CIC, we compared
the binding and catabolism of these CIC by MC and
HepG2. Gal-deficient IgA1-containing CIC were puri- Fig. 8. Internalization of a complex of IgG-Gal-deficient pIgA1 ()
and free Gal-deficient pIgA1 ( ) by human hepatoma cell line HepG2.fied from serum of an IgAN patient and control CIC
125I-labeled degalactosylated IgA1 was incubated with purified human
were isolated from serum of a healthy volunteer using IgG with anti-GalNAc activity. Free IgA1 was separated from the IgG-
IgA1 complexes by size-exclusion chromatography on Superose 6 col-size-exclusion chromatography [6]. These CIC (molecu-
umn. The fractions containing IgG bound to the radiolabeled IgA1lar mass about 700 to 900 kD) were radioiodinated, and
were detected by capture radioimmunoassay using Protein-G-coated
incubated with MC and HepG2. MC bound and internal- Removawell strips and gamma-counter detection. The proteins were
incubated with HepG2 cells at 37C for three hours, then the cells wereized more protein from the IgAN-CIC than from control
washed, treated with trypsin, and the radioactivity was measured withCIC. On the other hand, HepG2 cells bound less protein
a gamma counter and expressed per mg of cell protein.
from the IgAN-CIC (Fig. 7).
We hypothesized that the lower degree of internal-
ization of IgAN-CIC by hepatoma cells may be due to
the presence of GalNAc-specific IgG [6] that bound to In summary, these experiments indicated that MC
IgA1 and thus prevented IgA1 hinge region O-glycans bound and internalized IgA1-containing CIC via a recep-
[32] or Fc glycans [49, 50] from binding to ASGP-R on tor different from ASGP-R. MC bound more effectively
HepG2 cells. To test this hypothesis, we prepared in the CIC from an IgAN patient than that from a healthy
vitro 125I-labeled Gal-deficient IgA1 in a free form and control. Furthermore, CIC from an IgAN patient were
bound to GalNAc-specific IgG and used HepG2 cells to less efficiently internalized by hepatoma cells (HepG2)
assess the effect on internalization of the radiolabeled than control CIC. The IgG bound to Gal-deficient IgA1
IgA1. Complexing IgG with the IgA1 reduced the bind- apparently masks the binding sites on IgA1 glycans from
ASGP-R or interferes with an efficient internalization.ing and internalization by HepG2 cells (Fig. 8).
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Fig. 9. RT-PCR of FcR (CD89) transcripts
in MC and U937 cells. Total RNA was reverse-
transcribed and the cDNA was PCR-amplified
with CD89-specific primers. The amplicons
were separated on 2% agarose gel and photo-
graphed under UV light. Lane 1, molecular
size standards; lanes 2-5, -actin RT-PCR in
MC; lane 6, -actin RT-PCR in U937; lane 7,
RT-PCR of FcR transcripts in U937 with
three signals detected that correspond to the
a.1, a.2, and a.3 splicing variants; lanes 8-11,
RT-PCR of mRNA from MC grown under
various conditions failed to reveal any CD89-
specific signal (lanes 10, 11, MC were supple-
mented with insulin-like growth factor; lanes
9, 10, 5% glucose was added to the storage
medium).
CD89 and ASGP-R mRNA expression in MC mune deposits originate from CIC includes: (a) IgA1,
but not IgA2, is present in CIC in the circulation of mostTo determine a possible involvement of CD89 in bind-
IgAN patients [4, 5] and in their mesangial deposits [55];ing IgA to MC, RT-PCR was used to examine whether
(b) shared idiotypic determinants are expressed on CICthe CD89 gene is transcribed in MC. Total RNA isolated
and in mesangial deposits [56], however, without a dis-from MC grown with, or without, insulin-like growth fac-
ease-specific idiotype [57]; (c) Gal-deficient IgA1 is pres-tor and from U937 cells served as templates for RT
ent in CIC [6, 16, 45–48] and mesangial deposits [18, 19]followed by PCR amplification with CD89-specific prim-
in IgAN; and (d) Gal-deficient IgA1 is also found in theers. The results did not indicate the presence of CD89
circulation of Henoch-Scho¨nlein purpura patients, butmRNA in MC, although all three major splicing prod-
only in those with clinical nephritis [58].ucts, a.1, a.2, and a.3, (observed as PCR amplicons of
We have postulated that aberrant glycosylation of theabout 0.9 kb, 0.85 kb, and 0.62 kb, respectively) of CD89
hinge region of some IgA1 molecules of IgAN patientsmRNA were detected in samples from CD89-positive
exposes antigenic determinant(s) comprised of GalNAcU937 cells (Fig. 9). Adding insulin-like growth factor
linked to Ser or Thr of the polypeptide chain [16]. The(known to alter gene expression in MC [51] and used in
Gal-deficient IgA1 is, in turn, recognized by naturallyexperiments by others [20, 52, 53]) to the growth medium
occurring antibodies (IgG or IgA1 specific for GalNAc)or glucose [54] to the storage medium did not induce
that form CIC [6, 16], some of which deposit in theexpression of CD89 (Fig. 9).
mesangium. Indeed, two groups have detected highlyFurthermore, we determined whether MC express
undergalactosylated IgA1 in the kidney mesangial cellsASGP-R. cDNA prepared from total RNA from MC
of IgAN patients [18, 19]. While binding of human IgA1and HepG2 cell cultures served as templates for RT-
to human and rat MC has been well documented [20,PCR with two sets of primers specific for H1 and H2 sub-
24, 26, 27, 53], there had been no such study with CICunits of the ASGP-R. MC did not yield any specific sig-
containing undergalactosylated IgA1 isolated from seranals, while samples from HepG2 contained RNA for both
of IgAN patients.ASGP-R subunits, detected on an agarose gel as bands
This study compared uncomplexed Gal-deficient IgA1of about 0.6 kb and 0.5 kb, respectively (data not shown).
and CIC containing Gal-deficient IgA1 for the binding,In summary, MC expressed a receptor that bound
internalization, and catabolism by human MC. IntactIgA1 and IgA1-containing CIC, but this receptor did not
IgA1 or the Fc portion but not its Fab fragment inhibitedexhibit properties of FcR (CD89) or ASGP-R. Greater
binding of IgA1 to MC. This finding indicates that IgA1binding affinity of this receptor for Gal-deficient IgA1-
bound to MC through the Fc portion of the molecule.containing CIC compared with uncomplexed IgA may
MC bound asialo-agalacto-IgA1 better than normallyexplain mesangial deposition of these CIC in IgAN.
glycosylated IgA1 [59, 60]. Results of inhibition experi-
ments indicated that CIC from IgAN patients bound to
DISCUSSION MC more efficiently than complexes from healthy con-
trols, or than normally glycosylated IgA1 or asialo-aga-IgA deposits in the glomerular mesangium in IgAN
lacto-IgA1. Interestingly, binding of CIC to MC wasare apparently derived from CIC [2, 4, 5, 8, 10, 15, 17];
partially inhibited by normally glycosylated IgA1 or asi-however, the nature of antigens and ensuing CIC is un-
known. The evidence suggesting that the mesangial im- alo-agalacto-IgA1 but only marginally by IgG. These
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findings underscore the importance of IgA receptor(s) [20, 22, 23], we did not detect its mRNA in MC from
normal kidney tissue or commercial sources. Concordantfor binding of IgA1-CIC and are consistent with observa-
tions that IgG receptors are significantly expressed only with our results, other recent studies also failed to detect
CD89 on human MC [24–27]. Insulin-like growth factorafter MC activation or stimulation [61].
Our study showed for the first time that: (a) the IgAN was used by others as a supplement in the culture me-
dium [20] and, therefore, we also tested whether thisCIC containing Gal-deficient IgA1 bound to MC more
efficiently than uncomplexed IgA; (b) a greater amount growth factor would induce CD89 expression. However,
no induction was detected. FcR (CD89) has severalof CIC from an IgAN patient bound to MC than CIC
from a healthy control; and (c) a novel IgA Fc receptor isoforms that originate from alternative splicing [77].
Because some reports have shown conflicting data aboutwas important for CIC binding to MC. These findings
suggest a direct role for aberrant IgA1 glycosylation in the expression of CD89 on MC, we considered that an
expressed variant of CD89 may be a splicing version thatthe formation of CIC and their binding to MC. Prelimi-
nary experiments suggested reduced binding of CIC was not detected by the primers. Therefore, we designed
primers that could detect spliced variants, but found nofrom an IgAN patient to HepG2, implying that these
CIC may more easily escape hepatic catabolism. This such transcripts in MC. The reasons some investigators
detected CD89 are unclear, but may include differencescharacteristic may be one of the factors responsible for
increased circulating IgA1 levels in IgAN patients. in cultivation techniques, contamination with other cell
types (such as macrophages) known to express CD89,While MC in vitro bind IgA1 in a saturable manner
and the binding is inhibited by an excess of unlabeled or valid induction of CD89 or its variant [27].
Two other receptors have recently emerged as novelIgA1 [20, 21, 24, 26, 27, 52], the nature of the recep-
tor(s) has remained controversial. Several IgA receptors candidate IgA receptors on MC: CD71 (transferrin re-
ceptor) [65] and Fc/ receptor [66, 67]. We confirmedhave been identified on human cells: ASGP-R on he-
patocytes [28, 32]; pIgR on epithelial cells [62]; FcR the expression of CD71 mRNA by proliferating MC
in culture (not shown). However, MC bind both IgA(CD89) on monocytes, neutrophils, and eosinophils [29,
44, 63, 64]; CD71 (transferrin receptor) [65]; and Fc/ subclasses [27], while CD71 binds only IgA1 [65]. MC
bind pIgA1 better than mIgA [27], in contrast to thereceptor [66, 67]. The pIgR [26] and surface-bound ga-
lactosyltransferase can be excluded as possible candi- strong preference of CD71 for mIgA1 [65]. Furthermore,
CD71 is expressed by many proliferating cells, some ofdates because the bound proteins are not catabolic-
ally degraded [68–75] and pIgR binds polymeric but not which do not bind IgA1. Obviously the issues concerning
the role of CD71 on MC in binding Gal-deficient IgAmonomeric IgA.
Asialoglycoprotein receptor is a hetero-oligomer of or IgA-CIC remain to be addressed.
The other newly described candidate, Fc/ receptor,two homologous subunits, H1 and H2, encoded by sepa-
rate genes [30, 31]. ASGP-R on hepatocytes binds and appears to be transcribed by MC in vitro [67]. The ex-
pression of this receptor by MC or in renal tissue andinternalizes some glycans or glycoproteins with terminal
Gal and GalNAc residues. The internalized proteins are its role in binding IgA-CIC remain to be investigated,
although IgM does not inhibit IgA1 binding to MC [27].then catabolically degraded [28]. ASOR and IgA1 are ex-
cellent probes for ASGP-R as they are efficiently bound, This binding pattern may be explained if the variant of
the Fc/ receptor expressed by MC preferentially bindsinternalized, and catabolized by human hepatocytes and
the hepatoma cell line HepG2 [28, 29, 76]. To examine IgA. Clearly, the properties of this receptor need to be
investigated. A well-defined system, such as COS-7 cellsthe postulated presence of ASGP-R on human MC [21],
we compared binding, internalization, and catabolism of expressing the receptor [67], may be appropriate for
such a task.radiolabeled AS-IgA1 and ASOR by MC in primary cul-
ture and by a HepG2 cell line. Our experiments showed In conclusion, we detected binding, internalization, and
catabolism of IgA1 and IgA1-containing CIC by humanthat only HepG2 bound, internalized, and catabolized
both AS-IgA1 and ASOR, while MC bound and degra- MC, which was apparently independent of CD89 and
ASGP-R. While IgA1 is likely to bind to a single popula-ded AS-IgA1, but not ASOR. This finding was consistent
with our observation that only HepG2 cells exhibited tion of receptors, CIC can interact with MC in a more
complex manner that may involve other Ig-specific ormRNAs encoding the two ASGP-R subunits. Therefore,
it was unlikely that MC, under the conditions of our complement receptors. However, the hallmark of IgAN
is mesangial deposition of IgA1, and because purifiedexperiments, expressed ASGP-R. Other investigators re-
cently reached the same conclusion [26]. IgA1 was shown to bind to MC, it is very likely that a
specific, not yet biochemically characterized, IgA recep-FcR (CD89) is a glycoprotein expressed on myeloid
cells that binds both IgA subclasses [36]. Some investiga- tor is involved. Its similarity to a recently described novel
IgA receptor on human intestinal epithelial cells [78]tors have postulated that this receptor accounts for IgA1
binding to MC [20, 22, 23]. In contrast to earlier reports and the role of other IgA receptors [65, 67] remain to
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IgA1 in sera of IgA nephropathy patients is present in complexesbe investigated. Understanding the nature of the interac-
with IgG. Kidney Int 52:509–516, 1997
tion of IgA1 and its mesangial receptor may not only 17. Novak J, Julian BA, Tomana M, Mestecky J: Progress in molecu-
lar and genetic studies of IgA nephropathy. J Clin Immunol 21:310–explain how IgA1 and IgA1-containing CIC deposit in
327, 2001glomeruli and cause IgAN, but may also provide a theo-
18. Allen AC, Bailey EM, Brenchley PEC, et al: Mesangial IgA1
retical basis for developing disease-specific therapeutic in IgA nephropathy exhibits aberrant O-glycosylation: Observa-
tion in three patients. Kidney Int 60:969–973, 2001inhibitors.
19. Hiki Y, Odani H, Takahashi M, et al: Mass spectrometry proves
under-O-glycosylation of glomerular IgA1 in IgA nephropathy.
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